Myeloproliferative Chronic Myelomonocytic Leukemia

1 clinical trials · Condition

Record	Firm	Date
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (NCT05365035)	M.D. Anderson Cancer Center	2022-09-23

Every clearance here is in the API, with alerts when new ones post.